Synopsis
Synopsis
0
USDMF
0
JDMF
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Dihydrochloride, Flunarizine
2. Flunarizin
3. Flunarizine Dihydrochloride
4. Flunarizine Hydrochloride
5. Hydrochloride, Flunarizine
6. R 14950
7. R-14950
8. R14950
9. Sibelium
1. 52468-60-7
2. Sibelium
3. 1-(bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine
4. Flunarizinum [inn-latin]
5. Flunarizina [inn-spanish]
6. 40218-96-0
7. Flunarizine (inn)
8. (e)-1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine
9. R7pla2dm0j
10. 1-[bis(4-fluorophenyl)methyl]-4-[(e)-3-phenylprop-2-enyl]piperazine
11. Chembl30008
12. (e)-1-[bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine
13. Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (e)-
14. Flunarizine [inn]
15. 1-[bis(4-fluorophenyl)methyl]-4-[(2e)-3-phenylprop-2-en-1-yl]piperazine
16. Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (e)-
17. Flunarizine [inn:ban]
18. Dsstox_cid_25616
19. Dsstox_rid_81005
20. Dsstox_gsid_45616
21. Flunarazine
22. Narzine
23. Sibelium (tn)
24. Cas-52468-60-7
25. Einecs 257-937-5
26. Unii-r7pla2dm0j
27. 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-enyl)piperazine
28. (e)-1-(bis-(p-fluorophenyl)methyl)-4-cinnamylpiperazine
29. Flunarizine2hcl
30. Ncgc00018102-06
31. Einecs 254-842-0
32. Flunarizine [mi]
33. Prestwick2_000312
34. Prestwick3_000312
35. Spectrum5_001570
36. Lopac0_000527
37. Schembl43440
38. Schembl43441
39. Bspbio_000304
40. Bspbio_001341
41. Bspbio_003096
42. Flunarizine [who-dd]
43. Bpbio1_000336
44. Dtxsid6045616
45. Bcbcmap01_000120
46. Chebi:92209
47. Cid_6365505
48. 1-[bis(4-fluorophenyl)methyl]-4-[(e)-cinnamyl]piperazine
49. Chebi:135652
50. Hms1361d03
51. Hms1791d03
52. Hms1989d03
53. Hms2089h21
54. Hy-b0358
55. Tox21_110825
56. Bdbm50017702
57. Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-
58. Stl477617
59. Zinc19360739
60. 1-[bis(4-fluorophenyl)methyl]-4-[(2e)-3-phenyl-2-propenyl]piperazine
61. 4-((2e)-3-phenylprop-2-enyl)-1-[bis(4-fluorophenyl)methyl]piperazine
62. Akos015960783
63. Tox21_110825_1
64. Ac-1283
65. Ccg-204617
66. Db04841
67. Sdccgsbi-0050510.p004
68. Idi1_000043
69. Idi1_033811
70. Ncgc00018102-04
71. Ncgc00018102-05
72. Ncgc00018102-07
73. Ncgc00018102-08
74. Ncgc00018102-09
75. Ncgc00018102-10
76. Ncgc00018102-12
77. Ncgc00018102-24
78. Ncgc00024308-04
79. Ncgc00024308-05
80. Ncgc00024308-06
81. Ncgc00024308-07
82. As-75845
83. Sbi-0050510.p003
84. Cs-0013608
85. D07971
86. D93478
87. Ab00053586-15
88. Ab00053586_16
89. Ab00053586_17
90. A899896
91. Q416237
92. 1-[bis-(4-fluorophenyl)methyl]-4-cinnamylpiperazine
93. Brd-k12184470-300-01-8
94. Brd-k29582677-001-02-7
95. Brd-k29582677-300-05-6
96. Brd-k29582677-300-06-4
97. 1-[bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine
98. 1-[bis(4-fluorophenyl)methyl]-4-[(2z)-3-phenyl-2-propen-1-yl]piperazine
99. 1-[bis-(4-fluoro-phenyl)-methyl]-4-((e)-3-phenyl-allyl)-piperazine
100. Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2e)-3-phenyl-2-propenyl]-
101. 1-[bis-(4-fluoro-phenyl)-methyl]-4-(3-phenyl-allyl)-piperazine(flunarizine)
| Molecular Weight | 404.5 g/mol |
|---|---|
| Molecular Formula | C26H26F2N2 |
| XLogP3 | 6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 404.20640516 g/mol |
| Monoisotopic Mass | 404.20640516 g/mol |
| Topological Polar Surface Area | 6.5 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 487 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
N - Nervous system
N07 - Other nervous system drugs
N07C - Antivertigo preparations
N07CA - Antivertigo preparations
N07CA03 - Flunarizine
Absorption
85% following oral administration.
Hepatic, to two metabolites via N-dealylation and hydroxylation.
Flunarizine has known human metabolites that include 1-[bis(4-fluorophenyl)methyl]piperazine, bis(4-fluorophenyl)methanone, and p-Hydroxyflunarizine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
18 days
Flunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
78
PharmaCompass offers a list of Flunarizine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flunarizine manufacturer or Flunarizine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flunarizine manufacturer or Flunarizine supplier.
PharmaCompass also assists you with knowing the Flunarizine API Price utilized in the formulation of products. Flunarizine API Price is not always fixed or binding as the Flunarizine Price is obtained through a variety of data sources. The Flunarizine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Flunarizin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flunarizin, including repackagers and relabelers. The FDA regulates Flunarizin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flunarizin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Flunarizin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Flunarizin supplier is an individual or a company that provides Flunarizin active pharmaceutical ingredient (API) or Flunarizin finished formulations upon request. The Flunarizin suppliers may include Flunarizin API manufacturers, exporters, distributors and traders.
click here to find a list of Flunarizin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Flunarizin Drug Master File in Korea (Flunarizin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Flunarizin. The MFDS reviews the Flunarizin KDMF as part of the drug registration process and uses the information provided in the Flunarizin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Flunarizin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Flunarizin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Flunarizin suppliers with KDMF on PharmaCompass.
A Flunarizin CEP of the European Pharmacopoeia monograph is often referred to as a Flunarizin Certificate of Suitability (COS). The purpose of a Flunarizin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Flunarizin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Flunarizin to their clients by showing that a Flunarizin CEP has been issued for it. The manufacturer submits a Flunarizin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Flunarizin CEP holder for the record. Additionally, the data presented in the Flunarizin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Flunarizin DMF.
A Flunarizin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Flunarizin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Flunarizin suppliers with CEP (COS) on PharmaCompass.
A Flunarizin written confirmation (Flunarizin WC) is an official document issued by a regulatory agency to a Flunarizin manufacturer, verifying that the manufacturing facility of a Flunarizin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Flunarizin APIs or Flunarizin finished pharmaceutical products to another nation, regulatory agencies frequently require a Flunarizin WC (written confirmation) as part of the regulatory process.
click here to find a list of Flunarizin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Flunarizin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Flunarizin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Flunarizin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Flunarizin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Flunarizin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Flunarizin suppliers with NDC on PharmaCompass.
Flunarizin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Flunarizin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flunarizin GMP manufacturer or Flunarizin GMP API supplier for your needs.
A Flunarizin CoA (Certificate of Analysis) is a formal document that attests to Flunarizin's compliance with Flunarizin specifications and serves as a tool for batch-level quality control.
Flunarizin CoA mostly includes findings from lab analyses of a specific batch. For each Flunarizin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Flunarizin may be tested according to a variety of international standards, such as European Pharmacopoeia (Flunarizin EP), Flunarizin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flunarizin USP).
